Expert insights from Shagufta Shaheen, MD, on sequencing PRRT, everolimus, and cabozantinib after SSA progression in advanced ...
Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers. Biomarker status has ...
Switching to camizestrant 75 mg while continuing CDK4/6i significantly prolonged PFS to 16.0 vs 9.2 months (HR 0.44; P<.00001 ...
In this episode of Community Corner, Brittany Dulmage, MD, associate professor of dermatology and director of oncodermatology ...
Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, discusses the impactful conclusions ...
Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung ...
Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus ...
Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with ...
Among the most challenging are mutations in KEAP1 and STK11, which are frequently associated with a "cold" tumor ...
FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...
Confirmed RECIST v1.1 ORR favored varegacestat (56% vs 9%; P<.0001), with exploratory median best tumor-volume change of −83% ...
BELLA (NCT06906341) has completed enrollment testing triplet strategies such as adding bevacizumab and expanding evaluation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results